Drug Profile


Alternative Names: LY 297802; NNC 101053; NNC 111053

Latest Information Update: 09 Feb 2000

Price : $50

At a glance

  • Originator Novo Nordisk
  • Developer Eli Lilly
  • Class Analgesics
  • Mechanism of Action Muscarinic receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.


Highest Development Phases

  • No development reported Pain

Most Recent Events

  • 09 Feb 2000 No-Development-Reported for Pain in European Union (Unknown route)
  • 09 Feb 2000 No-Development-Reported for Pain in USA (Unknown route)
  • 30 May 1997 LY 297802 is now called Vedaclidine
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top